A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Amgen
Eli Lilly and Company
Astellas Pharma Inc
Hoffmann-La Roche
Hoffmann-La Roche
Qilu Pharmaceutical Co., Ltd.
GlaxoSmithKline
R-Pharm